Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16534093 | 0.80 | HCAR3 (0.49) | AURKAAURKBSCN9AGSK3BDYRK1A | |
| SCHEMBL16534089 | 0.79 | MAPK1 (0.51) | MAPK1LMNAATRALDH1A1RAB9A | |
| SCHEMBL6621424 | 0.77 | PTGDR2 (0.41) | AURKAAURKBSCN9AMAPK1KDM4E | |
| SCHEMBL1555895 | 0.77 | DYRK1A (0.43) | AURKAAURKBSCN9AGSK3BDYRK1A | |
| SCHEMBL15318181 | 0.76 | RAB9A (0.51) | SCN9ACA1CA2DYRK1AALDH1A1 | |
| SCHEMBL4697772 | 0.76 | ALDH1A1 (0.36) | AURKAAURKBMAP4K4SCN9ACA1 | |
| SCHEMBL17950342 | 0.76 | NPSR1 (0.51) | CA1CA2KDM4ELMNANPSR1 | |
| SCHEMBL14688543 | 0.75 | RET (0.47) | CA1CA2NPSR1ALDH1A1CCNA2 | |
| SCHEMBL4699047 | 0.75 | MAP4K4 (0.39) | AURKAAURKBMAP4K4CA1CA2 | |
| SCHEMBL17645589 | 0.74 | CCNA2 (0.44) | CCNA2CDK2CCNA1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110062758-B | Bicyclic dihydropyrimidine-carboxamide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-110062758-A | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | 奇斯药制品公司 | 2019-07-26 | — | — | CN | disclosed |
| WO-2018115383-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-28 | — | — | WO | disclosed |
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTISI S.p.A. (IT) | 2018-06-21 | — | — | US | disclosed |
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTISI S.p.A. (IT) | 2018-06-21 | — | — | US | disclosed |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | PFIZER INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | PFIZER INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-9388181-B2 | Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20160096837-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| WO-2016012896-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20140031362-A1 | TRI - AND TETRACYCLIC PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS ANTINEOPLASTIC AGENT | PIERRE FABRE MEDICAMENT (FR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031362-A1 | TRI - AND TETRACYCLIC PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS ANTINEOPLASTIC AGENT | PIERRE FABRE MEDICAMENT (FR) | 2014-01-30 | — | — | US | disclosed |
| CN-103534254-A | Tricyclic and tetracyclic pyrazolo [3,4-b ] pyridine compounds as antitumor agents | PF MEDICAMENT | 2014-01-22 | — | — | CN | disclosed |
| WO-2012140114-A1 | TRI- AND TETRACYCLIC PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS ANTINEOPLASTIC AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012140114-A1 | TRI- AND TETRACYCLIC PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS ANTINEOPLASTIC AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-10-18 | — | — | WO | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| EP-2488519-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | Pierre Fabre Médicament (FR) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045344-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2011-04-21 | — | — | WO | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | AURKA 848/4885AURKB 645/4885MAP4K4 164/4885 |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | DPYD, TYMP, ABCB1 | AURKA 106/4885AURKB 401/4885MAP4K4 264/4885 |
| US-20140031362-A1 | TRI - AND TETRACYCLIC PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS ANTINEOPLASTIC AGENT | TPMT, TYMP, PAICS | AURKA 227/4885AURKB 160/4885MAP4K4 1910/4885 |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | MAP4K2, MAP4K5, MAP4K3 | AURKA 265/4885AURKB 318/4885MAP4K4 11/4885 |
| US-20160096837-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS | TK1, CDK2, MAP4K2 | AURKA 219/4885AURKB 166/4885MAP4K4 24/4885 |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | DPYD, QDPR, ABCG2 | AURKA 889/4885AURKB 848/4885MAP4K4 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.